Research programme: serotonin reuptake inhibitors - Sosei R&D
Alternative Names: ARAK0029; ARAK0051; SD 726Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Sosei R&D
- Class Benzoxazines; Small molecules
- Mechanism of Action Adrenergic receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Back pain; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Back-pain in United Kingdom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in United Kingdom
- 30 Aug 2005 Arakis has been acquired by Sosei